Clinical trial
MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After…
NCT00256776 · European Society for Blood and Marrow Transplantation, Other · Terminated
Key facts
| NCT number | NCT00256776 |
|---|---|
| Title | MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation |
| Official title | A Randomized Controlled Study of Velcade (Bortezomib) Plus Thalidomide Plus Dexamethasone Compared to Thalidomide Plus Dexamethasone for the Treatment of Myeloma Patients Progressing or Relapsing After Autologous Transplantation |
| Lead sponsor | European Society for Blood and Marrow Transplantation, Other |
| Collaborators | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Industry Celgene Corporation |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Velcade (Bortezomib), Thalidomide, Dexamethasone |
| Enrollment | 269 |
| Start date | Jul 1, 2005 |
| Primary completion | Dec 1, 2013 |
| Completion | Dec 1, 2015 |
| First posted | Nov 22, 2005 |
| Last update posted | Oct 18, 2021 |
| Countries | Austria, Belgium, Czechia, France, Germany, Hungary, Israel, Italy, Switzerland, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: